Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Mandelic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mandelic Acid SCHEMBL28093049 | 0.93 | LMNA (0.64) | LMNAMAPK1SRCALDH1A1HPGD | |
| Mandelic Acid SCHEMBL4847480 | 0.91 | LMNA (0.82) | LMNAMAPK1SRCALDH1A1HPGD | |
| Mandelic Acid SCHEMBL30249457 | 0.87 | LMNA (0.82) | LMNAMAPK1SRCALDH1A1HPGD | |
| Mandelic Acid SCHEMBL7279536 | 0.87 | LMNA (0.90) | LMNAMAPK1SRCALDH1A1HPGD | |
| Mandelic Acid SCHEMBL5313046 | 0.87 | LMNA (1.00) | LMNAMAPK1SRCALDH1A1HPGD | |
| Mandelic Acid SCHEMBL21647917 | 0.87 | LMNA (1.00) | LMNAMAPK1SRCALDH1A1HPGD | |
| Mandelic Acid SCHEMBL165161 | 0.87 | LMNA (1.00) | LMNAMAPK1SRCALDH1A1HPGD | |
| Mandelic Acid SCHEMBL29777368 | 0.87 | LMNA (1.00) | LMNAMAPK1SRCALDH1A1HPGD | |
| Mandelic Acid SCHEMBL255601 | 0.87 | LMNA (1.00) | LMNAMAPK1SRCALDH1A1HPGD | |
| Mandelic Acid SCHEMBL1050 | 0.87 | LMNA (1.00) | LMNAMAPK1SRCALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119032181-A | Modified sophorolipids for improving the bioavailability of amino acids and methods of use | 轨迹方案IPCO有限责任公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-116209439-A | Substituted N- (2, 6-dioxopiperidin-3-yl) -1, 3-dioxoisoindolin-5-yl) arylsulfonamide analogs as cereblon modulators | 圣裘德儿童研究医院有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-112351973-A | Substituted 2-aminobenzimidazole analogs as anti-biofilm agents | 俄亥俄州国家创新基金会 | 2021-02-09 | — | — | CN | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
| WO-2010130708-A1 | BETA-LACTAMASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010084201-A1 | NOVEL DERIVATIVE OF ERYTHROMYCIN FOR THE TREATMENT AND DIAGNOSIS OF PRION DISEASE | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2010-07-29 | — | — | WO | disclosed |
| CN-100519528-C | Compounds with analgesic effect | ASTRA PHARMACEUTICALS INC (CA) | 2009-07-29 | — | — | CN | disclosed |
| US-20080176903-A1 | Novel Compounds with Analgesic Effect | ASTRAZENECA CANADA INC. (CA) | 2008-07-24 | — | — | US | disclosed |
| WO-2008049644-A1 | THYMIDINE ANALOGS FOR IMAGING | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-05-02 | — | — | WO | disclosed |
| EP-1916003-A1 | Thymidine analogs for imaging | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-30 | — | — | EP | disclosed |
| WO-1994006757-A1 | AGENTS ACTING AT CHOLECYSTOKININ RECEPTORS | WARNER-LAMBERT COMPANY (US) | 1994-03-31 | — | — | WO | disclosed |
| WO-1994004494-A1 | TACHYKININ ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-03-03 | — | — | WO | disclosed |
| US-5264419-A | N-substituted cycloalkyl and polycycloalkyl α-substituted TRP derivatives | WARNER-LAMBERT COMPANY (US) | 1993-11-23 | — | — | US | disclosed |
| EP-0546108-A4 | PRO-DRUGS FOR CCK ANTAGONISTS | — | 1993-09-22 | — | — | EP | disclosed |
| EP-0547178-A1 | NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 1993-06-23 | — | — | EP | disclosed |
| EP-0546108-A1 | PRO-DRUGS FOR CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1993-06-16 | — | — | EP | disclosed |
| WO-1992004045-A1 | NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992004038-A1 | PRO-DRUGS FOR CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
| WO-1992004320-A1 | N-SUBSTITUTED CYCLOALKYL AND POLYCYCLOALKYL ALPHA-SUBSTITUTED Trp DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
| EP-0071543-B1 | PIPERAZINE DERIVATIVES OF THEOBROMINE | LABORATOIRES SYNTEX (FR) | 1987-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | LMNA 4022/4885MAPK1 2222/4885SRC 1286/4885 |
| US-20080176903-A1 | Novel Compounds with Analgesic Effect | OPRL1, OPRK1, OPRM1 | LMNA 4235/4885MAPK1 4134/4885SRC 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.